BME · BlackRock Health Sciences Trust
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Asset Management — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BME
this stock
BlackRock Health Sciences Trust
|
$577.06M | +12.1% | — | — | 0.3% |
|
BLK
BlackRock, Inc.
|
$382.87B | +9.1% | +16.2% | 28.2 | 0.6% |
|
BX
Blackstone Inc.
|
$108.56B | -6.8% | +9.2% | 32.4 | 2.9% |
|
KKR
KKR & Co. Inc.
|
$98.13B | -14.2% | -11.0% | — | 1.4% |
|
BN
BROOKFIELD Corp /ON/
|
$92.82B | -9.7% | — | — | 0.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BME | +0.7% | +5.9% | +11.8% | +6.0% | +12.1% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -0.5% | +1.9% | -2.9% | +2.8% | -1.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.